|
1
|
Spirtas R, Heineman EF, Bernstein L, Beebe
GW, Keehn RJ, Stark A, Harlow BL and Benichou J: Malignant
mesothelioma: Attributable risk of asbestos exposure. Occup Environ
Med. 51:804–811. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Björkqvist AM, Tammilehto L, Nordling S,
Nurminen M, Anttila S, Mattson K and Knuutila S: Comparison of DNA
copy number changes in malignant mesothelioma, adenocarcinoma and
large-cell anaplastic carcinoma of the lung. Br J Cancer.
77:260–269. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Taniguchi T, Karnan S, Fukui T, Yokoyama
T, Tagawa H, Yokoi K, Ueda Y, Mitsudomi T, Horio Y, Hida T, et al:
Genomic profiling of malignant pleural mesothelioma with
array-based comparative genomic hybridization shows frequent
non-random chromosomal alteration regions including JUN
amplification on 1p32. Cancer Sci. 98:438–446. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chiosea S, Krasinskas A, Cagle PT,
Mitchell KA, Zander DS and Dacic S: Diagnostic importance of 9p21
homozygous deletion in malignant mesotheliomas. Mod Pathol.
21:742–747. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Toyooka S, Kishimoto T and Date H:
Advances in the molecular biology of malignant mesothelioma. Acta
Med Okayama. 62:1–7. 2008.PubMed/NCBI
|
|
6
|
Fleury-Feith J, Lecomte C, Renier A,
Matrat M, Kheuang L, Abramowski V, Levy F, Janin A, Giovannini M
and Jaurand MC: Hemizygosity of Nf2 is associated with increased
susceptibility to asbestos-induced peritoneal tumours. Oncogene.
22:3799–3805. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nemoto H, Tate G, Kishimoto K, Saito M,
Shirahata A, Umemoto T, Matsubara T, Goto T, Mizukami H, Kigawa G,
et al: Heterozygous loss of NF2 is an early molecular alteration in
well-differentiated papillary mesothelioma of the peritoneum.
Cancer Genet. 205:594–598. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Metcalf RA, Welsh JA, Bennett WP, et al:
p53 and Kirsten-ras mutations in human mesothelioma cell lines.
Cancer Res. 52:2610–2615. 1992.PubMed/NCBI
|
|
9
|
Papp T, Schipper H, Pemsel H, et al:
Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes
in primary human malignant mesotheliomas. Int J Oncol. 18:425–433.
2001.PubMed/NCBI
|
|
10
|
Toyooka S, Pass HI, Shivapurkar N,
Fukuyama Y, et al: Aberrant methylation and simian virus 40 tag
sequences in malignant mesothelioma. Cancer Res. 61:5727–5730.
2001.PubMed/NCBI
|
|
11
|
Kobayashi N, Toyooka S, Yanai H, et al:
Frequent p16 inactivation by homozygous deletion or methylation is
associated with a poor prognosis in Japanese patients with pleural
mesothelioma. Lung Cancer. 62:120–125. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Goto Y, Shinjo K, Kondo Y, et al:
Epigenetic profiles distinguish malignant pleural mesothelioma from
lung adenocarcinoma. Cancer Res. 69:9073–9082. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Addis B and Roche H: Problems in
mesothelioma diagnosis. Histopathology. 54:55–68. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gee GV, Koestler DC, Christensen BC, et
al: Downregulated microRNAs in the differential diagnosis of
malignant pleural mesothelioma. Int J Cancer. 127:2859–2869. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Betta PG, Magnani C, Bensi T, Trincheri NF
and Orecchia S: Immunohistochemistry and molecular diagnostics of
pleural malignant mesothelioma. Arch Pathol Lab Med. 136:253–261.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Husain AN, Colby T, Ordonez N, Krausz T,
Attanoos R, Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac
LR, et al: International Mesothelioma Interest Group: Guidelines
for pathologic diagnosis of malignant mesothelioma: 2012 update of
the consensus statement from the International Mesothelioma
Interest Group. Arch Pathol Lab Med. 137:647–667. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamamoto H, Shigematsu H, Nomura M,
Lockwood WW, Sato M, Okumura N, Soh J, Suzuki M, Wistuba II, Fong
KM, et al: PIK3CA mutations and copy number gains in human lung
cancers. Cancer Res. 68:6913–6921. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Soh J, Okumura N, Lockwood WW, Yamamoto H,
Shigematsu H, Zhang W, Chari R, Shames DS, Tang X, MacAulay C, et
al: Oncogene mutations, copy number gains and mutant allele
specific imbalance (MASI) frequently occur together in tumor cells.
PLoS One. 4:e74642009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kubo T, Yamamoto H, Lockwood WW, Valencia
I, Soh J, Peyton M, Jida M, Otani H, Fujii T, Ouchida M, et al:
MET gene amplification or EGFR mutation activate
MET in lung cancers untreated with EGFR tyrosine
kinase inhibitors. Int J Cancer. 124:1778–1784. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sasaki H, Hikosaka Y, Kawano O, Moriyama
S, Yano M and Fujii Y: Evaluation of Kras gene mutation and copy
number gain in non-small cell lung cancer. J Thorac Oncol. 6:15–20.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao X, Weir BA, LaFramboise T, Lin M,
Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG,
et al: Homozygous deletions and chromosome amplifications in human
lung carcinomas revealed by single-nucleotide polymorphism array
analysis. Cancer Res. 65:5561–5570. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yuan P, Kadara H, Behrens C, Tang X, Woods
D, Solis LM, Huang J, Spinola M, Dong W, Yin G, et al:
Sex-determining region Y-Box 2 (SOX2) is a potential
cell-lineage gene highly expressed in the pathogenesis of squamous
cell carcinomas of the lung. PLoS One. 5:e91122010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kohler LH, Mireskandari M, Knösel T,
Altendorf-Hofmann A, Kunze A, Schmidt A, Presselt N, Chen Y and
Petersen I: FGFR1 expression and gene copy numbers in human
lung cancer. Virchows Arch. 461:49–57. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Heist RS, Mino-Kenudson M, Sequist LV,
Tammireddy S, Morrissey L, Christiani DC, Engelman JA and Iafrate
AJ: FGFR1 amplification in squamous cell carcinoma of the
lung. J Thorac Oncol. 7:1775–1780. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sasaki H, Yokota K, Hikosaka Y, Moriyama
S, Yano M and Fujii Y: Increased SOX2 copy number in lung
squamous cell carcinomas. Exp Ther Med. 3:44–48. 2012.PubMed/NCBI
|
|
26
|
Jagadeeswaran R, Ma PC, Seiwert TY,
Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R,
Paganuzzi M, Puntoni R, et al: Functional analysis of c-met
hepatocyte growth factor pathway in malignant pleural mesothelioma.
Cancer Res. 66:352–361. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in
lung cancer by activating ERBB3 signaling. Science. 316:1039–1043.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Asano H, Toyooka S, Tokumo M, Ichimura K,
Aoe K, Ito S, Tsukuda K, Ouchida M, Aoe M, Katayama H, et al:
Detection of EGFR gene mutation in lung cancer by
mutant-enriched polymerase chain reaction assay. Clin Cancer Res.
12:43–48. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Okuda K, Sasaki H, Kawano O, Yukiue H,
Yokoyama T, Yano M and Fujii Y: Epidermal growth factor receptor
gene mutation, amplification and protein expression in malignant
pleural mesothelioma. J Cancer Res Clin Oncol. 134:1105–1111. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rena O, Boldorini LR, Gaudino E and
Casadio C: Epidermal growth factor receptor overexpression in
malignant pleural mesothelioma: Prognostic correlations. J Surg
Oncol. 104:701–705. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Enomoto Y, Kasai T, Takeda M, Takano M,
Morita K, Kadota E, Iizuka N, Maruyama H, Haratake J, Kojima Y, et
al: A comparison of epidermal growth factor receptor expression in
malignant peritoneal and pleural mesothelioma. Pathol Int.
62:226–231. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takeda M, Kasai T, Enomoto Y, Takano M,
Morita K, Kadota E, Iizuka N, Maruyama H and Nonomura A: Genomic
gains and losses in malignant mesothelioma demonstrated by FISH
analysis of paraffin-embedded tissues. J Clin Pathol. 65:77–82.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Destro A, Ceresoli GL, Falleni M, Zucali
PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V,
Alloisio M, et al: EGFR overexpression in malignant pleural
mesothelioma. An immunohistochemical and molecular study with
clinico-pathological correlations. Lung Cancer. 51:207–215. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pache JC, Janssen YM, Walsh ES, Quinlan
TR, Zanella CL, Low RB, Taatjes DJ and Mossman BT: Increased
epidermal growth factor-receptor protein in a human mesothelial
cell line in response to long asbestos fibers. Am J Pathol.
152:333–340. 1998.PubMed/NCBI
|
|
35
|
Cortese JF, Gowda AL, Wali A, Eliason JF,
Pass HI and Everson RB: Common EGFR mutations conferring
sensitivity to gefitinib in lung adenocarcinoma are not prevalent
in human malignant mesothelioma. Int J Cancer. 118:521–522. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Velcheti V, Kasai Y, Viswanathan AK,
Ritter J and Govindan R: Absence of mutations in the epidermal
growth factor receptor (EGFR) kinase domain in patients with
mesothelioma. J Thorac Oncol. 4:5592009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mezzapelle R, Miglio U, Rena O, Paganotti
A, Allegrini S, Antona J, Molinari F, Frattini M, Monga G, Alabiso
O, et al: Mutation analysis of the EGFR gene and downstream
signalling pathway in histologic samples of malignant pleural
mesothelioma. Br J Cancer. 108:1743–1749. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tsao MS, Sakurada A, Cutz JC, Zhu CQ,
Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, et
al: Erlotinib in lung cancer - molecular and clinical predictors of
outcome. N Engl J Med. 353:133–144. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Moroni M, Veronese S, Benvenuti S,
Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M,
Siena S and Bardelli A: Gene copy number for epidermal growth
factor receptor (EGFR) and clinical response to
antiEGFR treatment in colorectal cancer: a cohort study.
Lancet Oncol. 6:279–286. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Govindan R, Kratzke RA, Herndon JE,
Niehans GA, Vollmer R, Watson D, Green MR and Kindler HL: Cancer
and Leukemia Group B (CALGB 30101): Gefitinib in patients with
malignant mesothelioma: A phase II study by the Cancer and Leukemia
Group B. Clin Cancer Res. 11:2300–2304. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Garland LL, Rankin C, Gandara DR, Rivkin
SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA and
Borden EC: Phase II study of erlotinib in patients with malignant
pleural mesothelioma: A Southwest Oncology Group Study. J Clin
Oncol. 25:2406–2413. 2007. View Article : Google Scholar : PubMed/NCBI
|
